Qin Dailei, Xi Pu, Huang Kewei, Jiang Lingmin, Yao Zehui, Wei Ran, Li Shengping
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Med (Lausanne). 2024 Dec 6;11:1486750. doi: 10.3389/fmed.2024.1486750. eCollection 2024.
Radical resection is the only curative method for patients with pancreatic adenocarcinoma (PDAC). However, nearly 85% of PDAC patients suffer from local or distant recurrence within 5 years after curative resection. The progression of recurrent lesions accelerates the mortality rate in PDAC patients. However, the influence of clinicopathological factors on post-progression-free survival (PPFS), defined as the period from tumor recurrence to the timing of the progression of recurrent lesions, has rarely been discussed. The present study aimed to explore the independent prognostic factors for PPFS and construct a nomogram for PPFS prediction.
The 200 recurrent PDAC patients were divided into training and validation groups by leave-one-out cross-validation. The patients' clinicopathological characteristics were compared through a chi-square test. Meanwhile, these factors were enrolled in the univariate and multivariate COX regression to find the independent prognostic factors of PPFS. Moreover, the Kaplan-Meier survival analysis based on the independent prognostic factors was performed. Finally, we constructed a nomogram model for PPFS prediction, followed by an effectiveness examination.
PDAC patients who received multi-agent chemotherapy after surgery showed a longer PPFS than the single-agent chemotherapy group. PDAC patients who received multi-agent chemotherapy after recurrence showed a similar PPFS compared to the single-agent chemotherapy group. Local recurrence with distant metastases, early recurrence, lympho-vascular invasion, higher T stage, and higher N stage predicted shorter PPFS in recurrent PDAC patients. Finally, a nomogram to indicate the progression of recurrent lesions was constructed.
Multi-agent chemotherapy is recommended for PDAC patients after surgery. Meanwhile, single-agent chemotherapy also deserves consideration after tumor recurrence. Moreover, the nomogram could be used in PPFS prediction.
根治性切除是胰腺导管腺癌(PDAC)患者的唯一治愈方法。然而,近85%的PDAC患者在根治性切除术后5年内出现局部或远处复发。复发病变的进展加速了PDAC患者的死亡率。然而,临床病理因素对无进展生存期(PPFS)的影响,即从肿瘤复发到复发病变进展的时间段,很少被讨论。本研究旨在探讨PPFS的独立预后因素,并构建PPFS预测列线图。
采用留一法交叉验证将200例复发性PDAC患者分为训练组和验证组。通过卡方检验比较患者的临床病理特征。同时,将这些因素纳入单因素和多因素COX回归分析,以寻找PPFS的独立预后因素。此外,基于独立预后因素进行Kaplan-Meier生存分析。最后,构建PPFS预测列线图模型,并进行有效性检验。
术后接受多药化疗的PDAC患者的PPFS长于单药化疗组。复发后接受多药化疗的PDAC患者的PPFS与单药化疗组相似。局部复发伴远处转移、早期复发、淋巴管侵犯、较高的T分期和较高的N分期预示着复发性PDAC患者的PPFS较短。最后,构建了一个指示复发病变进展的列线图。
推荐PDAC患者术后进行多药化疗。同时,肿瘤复发后单药化疗也值得考虑。此外,该列线图可用于PPFS预测。